Novoron

Drug Discovery · Biotechnology
$15.2Mtotal raised · 6 rounds on record
$12.1Mlatest round · Venture round · Dec 2022 · 3 yr ago
$3.5Mgrants · 4 grants · CORDIS
50+team · employees, estimated range

Overview

Novoron Bioscience develops new therapeutic approaches to address neurological damage or disease in the central nervous system (CNS).

Funding and backers

Total raised
$15.2M
6 rounds on record
Latest round
$12.1M
Venture round · Dec 2022 · 3 yr ago
Team
51-200
employees, estimated range
Grants
$3.5M
4 grants · CORDIS
The money's age
Long since its last round
46 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 16, 2025 Won a grant $1.3M · CORDIS Dec 8, 2022 Raised a round Venture round $12.1M · SEC Form D Sep 1, 2021 Won a grant $845k · CORDIS Sep 15, 2019 Won a grant $707k · CORDIS Apr 1, 2018 Won a grant $695k · CORDIS
Funding rounds
RoundDateAmountInvestorsSource
Grant Sep 2025 $1.3M — CORDIS
Venture round Dec 2022 $12.1M — SEC Form D
Grant Sep 2021 $845k — CORDIS
Venture round Jun 2021 $3M — SEC Form D
Grant Sep 2019 $707k — CORDIS
Grant Apr 2018 $695k — CORDIS
Registers and programsofficial lists and records that name the company
Legal entity Novoron Bioscience, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Travis StilesExecutive Officer, DirectorSEC Form D
Shawn GahrExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Inveready
backs Ability Pharma, CONNECTA Therapeutics
Andreessen Horowitz
backs GateBioscience
Plug and Play
backs NEXI Biotech Inc
GV
backs GateBioscience
ARCH Venture Partners
backs GateBioscience
Walden Catalyst Ventures
backs GreenstoneBio
Similar startupsby what they do, their industry and backers
GreenstoneBioFounded 2021 · 51-200 employees
Greenstone Biosciences drives the NAMs revolution using human-relevant iPSC technologies and the world’s largest biobank of 2,500+ donors.
GateBioscienceFounded 2021 · 11-50 employees
Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination. Molecular Gates are small molecule drugs that…
Autobahn TherapeuticsSeries C $100M · 2 yr ago
Autobahn aims to improve life health for people affected by CNS disorders by driving the regenerative power of the human body.
PROSIONVenture round · 3 yr ago · Founded 2020
PROSION Therapeutics is a drug development company that utilises cutting-edge technology to unlock so far undruggable targets and address…
NEXI Biotech Inc
NEXI Biotech builds translational in vitro neural models that turn preclinical research into clinical insight — so the next generation of…
PsileraSeed $8.8M · 5 mo ago · Founded 2021 · 11-50 employees
Psilera is a biotechnology company developing groundbreaking first-in-class treatments for neurological disorders by creating a new class…

Financials

Total raised
$18.7M
Latest round
Grant
Funding rounds
6
Funding rounds
Round Announced Amount
Grant 2025 $1.3M Details
Venture - Series Unknown 2022 $12.1M Details
Grant 2021 $845k Details
Venture - Series Unknown 2021 $3M Details
Grant 2019 $707k Details
Grant 2018 $695k Details

People

Travis Stiles
Executive Officer, Director
SEC Form D
Shawn Gahr
Executive Officer, Director
SEC Form D
Michael Goguen
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego United States
HQ
Shawn Gahr
50-200 est. staff
1155 Island Avenue, Suite 100, San Diego, CA 92101
company site